 |
Joele Frank is piloting Reinvent Technology Partners’ deal to acquire Joby Aviation, maker of electrical vertical takeoff/landing aircraft (eVTOL).
RTP is the SPAC of LinkedIn co-founder Reid Hoffman and Zynga founder Mark Pincus. The deal values Joby at $6.6B.
Joby plans to develop an air taxi service, carrying passengers on trips from five to 150 miles.
Its goal is to “revolutionize how people move by unlocking the possibility to leapfrog sustainably over the gridlock below in its piloted, four-passenger, emissions-free aircraft."
Joby has completed more than 1,000 test flights during the past decade and in 2020 became the first company to file eVTOL certification with the Federal Aviation Administration.
The company hopes to launch commercial service in the US in 2024, before scaling globally using its own “vertiports” and existing heliport/airport infrastructure.
Joby, which has partnerships with Toyota and Uber, sees a potential $500B market in the US and a more than $1T opportunity overseas.
Hoffman believes “Joby is well-positioned to create a transformative new human-centered mobility network."
Joele Frank, Wilkinson Brimmer Katcher has Ed Trissel, Jon Keehner and Scott Bisang representing RTP.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
